Theravance Biopharma has opened a corporate office in Dublin, Ireland and plans to hire 30 new employees over the next 2 years, the company said.
The company also announced that it and its partner Mylan had presented additional data from 2 Phase 3 trials of TD-4208 inhaled revefenacin at the 2017 CHEST meeting. Topline results from the Phase 3 trials were released in October 2016.
Theravance Biopharma Ireland President Ann Brady said, “This important expansion within Ireland provides an opportunity to tap into the extensive biopharmaceutical talent pool within the country. Our Irish team looks forward to helping to build on Theravance Biopharma’s legacy of scientific expertise, advance our pipeline of potential therapies in multiple disease areas, and ultimately change the way serious diseases are treated.”
Read the Theravance Biopharma press release.
